Literature DB >> 33206964

Late-onset and long-lasting autoimmune neutropenia: an analysis from the Italian Neutropenia Registry.

Francesca Fioredda1, Gioacchino Andrea Rotulo1, Piero Farruggia2, Francesca Dagliano1, Marta Pillon3, Angela Trizzino2, Lucia Notarangelo4, Laura Luti5, Tiziana Lanza1, Paola Terranova1, Marina Lanciotti1, Isabella Ceccherini6, Alice Grossi6, Laura Porretti7, Federico Verzegnassi8, Elena Mastrodicasa9, Angelica Barone10, Giovanna Russo11, Sonia Bonanomi12, Gianluca Boscarol13, Andrea Finocchi14,15, Marinella Veltroni16, Ugo Ramenghi17, Daniela Onofrillo18, Baldassare Martire19, Roberta Ghilardi20, Paola Giordano21, Saverio Ladogana22,23, Nicoletta Marra24, Sabrina Zanardi1,25, Fabian Beier26, Maurizio Miano1, Carlo Dufour1.   

Abstract

Primary autoimmune neutropenia (pAN) is typified by onset in early infancy and a mild/moderate phenotype that resolves within 3 years of diagnosis. In contrast, secondary AN is classically an adult disease associated with malignancy, autoimmunity, immunodeficiency, viral infection, or drugs. This study describes a cohort of 79 children from the Italian Registry who, although resembling pAN, did not fully match the criteria for pAN because neutropenia either appeared after age 5 years (LO-Np) or lasted longer than 3 years (LL-Np). These 2 categories compared with classical pAN showed a far inferior rate of resolution (P < .001), lower severity of neutropenia (P = .03), leukopenia (P < .001), lymphopenia (P < .001) with low B+ (P = .001), increased need of granulocyte colony-stimulating factor (P = .04), and increased frequency of autoimmunity over the disease course (P < .001). A paired comparison between LO-Np and LL-Np suggested that LO-Np had a lower rate of resolution (P < .001) and lower white blood cell (P < .001) and lymphocyte (P < .001) values, higher occurrence of apthae (P = .008), and a stronger association with autoimmune diseases/markers (P = .001) than LL-Np, thus suggesting a more pronounced autoimmune signature for LO-Np. A next-generation sequencing panel applied in a small subgroup of LO-Np and LL-Np patients identified variants related to immune dysregulations. Overall, these findings indicate that there are important differences among pAN LL-Np and LO-Np. Forms rising after 3 years of age, with low tendency to resolution, require tight monitoring and extensive immune investigations aimed to early identify underlying immunologic disease.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2020        PMID: 33206964      PMCID: PMC7686904          DOI: 10.1182/bloodadvances.2020002793

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  16 in total

Review 1.  How I treat common variable immune deficiency.

Authors:  Charlotte Cunningham-Rundles
Journal:  Blood       Date:  2010-03-23       Impact factor: 22.113

2.  Congenital and acquired neutropenias consensus guidelines on therapy and follow-up in childhood from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato-Oncologia Pediatrica).

Authors:  Francesca Fioredda; Michaela Calvillo; Sonia Bonanomi; Tiziana Coliva; Fabio Tucci; Piero Farruggia; Marta Pillon; Baldassarre Martire; Roberta Ghilardi; Ugo Ramenghi; Daniela Renga; Giuseppe Menna; Anna Pusiol; Angelica Barone; Eleonora Gambineri; Giovanni Palazzi; Gabriella Casazza; Marina Lanciotti; Carlo Dufour
Journal:  Am J Hematol       Date:  2011-12-27       Impact factor: 10.047

3.  Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans.

Authors:  U Salzer; H M Chapel; A D B Webster; Q Pan-Hammarström; A Schmitt-Graeff; M Schlesier; H H Peter; J K Rockstroh; P Schneider; A A Schäffer; L Hammarström; B Grimbacher
Journal:  Nat Genet       Date:  2005-07-10       Impact factor: 38.330

4.  The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity.

Authors:  Markus G Seidel; Gerhard Kindle; Benjamin Gathmann; Isabella Quinti; Matthew Buckland; Joris van Montfrans; Raphael Scheible; Stephan Rusch; Lukas M Gasteiger; Bodo Grimbacher; Nizar Mahlaoui; Stephan Ehl
Journal:  J Allergy Clin Immunol Pract       Date:  2019-02-15

5.  Primary autoimmune neutropenia in children: a study of neutrophil antibodies and clinical course.

Authors:  M Bruin; A Dassen; D Pajkrt; L Buddelmeyer; T Kuijpers; M de Haas
Journal:  Vox Sang       Date:  2005-01       Impact factor: 2.144

6.  Diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases.

Authors:  J Bux; G Behrens; G Jaeger; K Welte
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

7.  Neutrophil antibody specificity in different types of childhood autoimmune neutropenia.

Authors:  M C Bruin; A E von dem Borne; R Y Tamminga; M Kleijer; L Buddelmeijer; M de Haas
Journal:  Blood       Date:  1999-09-01       Impact factor: 22.113

8.  Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes.

Authors:  Li Zhang; Lin Radigan; Ulrich Salzer; Timothy W Behrens; Bodo Grimbacher; George Diaz; James Bussel; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol       Date:  2007-11       Impact factor: 10.793

9.  External quality assessment of human neutrophil antigen (HNA)-specific antibody detection and HNA genotyping from 2000 to 2012.

Authors:  G Lucas; L Porcelijn; Y L Fung; F Green; A Reil; M Hopkins; R Schuller; A Green; M de Haas; J Bux
Journal:  Vox Sang       Date:  2013-05-11       Impact factor: 2.144

10.  TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes.

Authors:  Amanda J Walne; Tom Vulliamy; Richard Beswick; Michael Kirwan; Inderjeet Dokal
Journal:  Blood       Date:  2008-07-30       Impact factor: 22.113

View more
  3 in total

1.  Outcomes for patients with severe chronic neutropenia treated with granulocyte colony-stimulating factor.

Authors:  David C Dale; Audrey Anna Bolyard; James A Shannon; James A Connelly; Daniel C Link; Mary Ann Bonilla; Peter E Newburger
Journal:  Blood Adv       Date:  2022-07-12

2.  Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine.

Authors:  Ramon Diez-Feijóo; Juan Jose Rodríguez-Sevilla; Concepcion Fernández-Rodríguez; Solange Flores; Carmen Raya; Ana Ferrer; Luis Colomo; Antonio Salar
Journal:  Front Immunol       Date:  2022-01-10       Impact factor: 7.561

3.  Targeted NGS Yields Plentiful Ultra-Rare Variants in Inborn Errors of Immunity Patients.

Authors:  Alice Grossi; Maurizio Miano; Marina Lanciotti; Francesca Fioredda; Daniela Guardo; Elena Palmisani; Paola Terranova; Giuseppe Santamaria; Francesco Caroli; Roberta Caorsi; Stefano Volpi; Marco Gattorno; Carlo Dufour; Isabella Ceccherini
Journal:  Genes (Basel)       Date:  2021-08-24       Impact factor: 4.096

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.